**PROLIA (denosumab)**

Effective Date: 1/28/14

Date Developed: 1.28.14 by Robert Sterling, MD

Last Approval Date: 01.26.16, 01.24.17

**Prolia** is a genetically engineered human IgG monoclonal antibody which inhibits proteins necessary for osteoclast activation, thereby inhibiting bone resorption (up to 85%).

**Authorization:** postmenopausal women at high risk for fracture who are intolerant of or unresponsive to other therapies; treatment of bone loss in women with breast cancer who are receiving aromatase inhibitor therapy; men with osteoporosis at high risk for fracture; treatment of bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer.

Not indicated for prevention of skeletal-related events with multiple myeloma.

Unlabeled Use: treatment of bone destruction caused by rheumatoid arthritis. (See VCHCP policy on Coverage of Prescription Medication for Off-Label Use.)

**Dosing:** 60mg subcutaneously every six months

**PRECAUTIONS:** all patients should receive calcium 1000 mg and at least 400 IU vitamin D daily; correct hypocalcemia and monitor serum calcium, especially in dialysis patients; monitor serum phosphorus; osteonecrosis of the jaw (ONJ) after tooth extraction or dental abscess; back pain; arthralgias; fatigue

**DRUG INTERACTIONS:** may increase the risk of infections in patients taking immunosuppressants.
REFERENCES


Revision History:
Date Reviewed/No Updates: 01.13.15 by C. Sanders, MD
Date Approved by P&T Committee: 01.27.15
Date Reviewed/No Updates: 01.26.16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.26.16
Date Reviewed/No Updates: 01.24.17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.24.17
<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>